| Project/Area Number |
22590339
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Human pathology
|
|---|
| Research Institution | Fujita Health University |
|---|
Principal Investigator |
INADA Kenichi 藤田保健衛生大学, 医学部, 准教授 (70246081)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
水谷 泰嘉 藤田保健衛生大学, 医学部, 助教 (10546229)
|
|---|
| Project Period (FY) |
2010 – 2012
|
| Project Status |
Completed (Fiscal Year 2012)
|
| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
|---|
| Keywords | microRNA / in situ hybridization / LNA/DNA オリゴプローブ / thyramide / 病理組織切片 / 食道扁平上皮癌 / Brm / Egr1 / miRNA199a / LNAプローブ / 免疫組織化学 / 胃癌 / C型肝硬変 / C型肝細胞癌 / microRNA199a / LNA/DNAオリゴプローブ / tyramide |
|---|
| Research Abstract |
Although we examined various tumors including esophageal cancer (squamous cell carcinoma), gastric cancer (adenocarcinoma), ovarian cancer (adenocarcinoma), and hepatocellular carcinoma in this study, no apparent biological interrelationship between microRNAs and their targeted specific proteins was revealed except esophageal cancer. We supposed that the central reason for the failure to detect the interrelationship was deterioration of ISH probes and unexpected change of company that supplied them. On the contrary, we found that microRNA 199a, Brm, and Egr1 constructed double-negative feed in esophageal cancer, suggesting that they were mutually related in the process of esophageal carcinogenesis, cancer development, and its progression. But no special relationship was found between them and tumor stage. We are continuously studying about other tumors both epithelial and nonepithelial and various precancerous lesions because this research method is very unique.
|
